XML 27 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information
 3 Months Ended
Mar. 31, 2017
Segment Reporting [Abstract]  
Segment Information
Segment Information
Effective as of the second quarter of 2016 and in connection with the launch of HOTSHOT, the Company operates as two reportable segments:
•
The Consumer Operations segment, which reflects the total revenue and costs and expenses related to HOTSHOT and the Company's consumer operations.
•
The Drug Development segment, which reflects the costs and expenses related to the Company's efforts to develop innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions.
The Company discloses information about its reportable segments based on the way that the Company's Chief Operating Decision Maker, who the Company has identified as the Chief Executive Officer, and management, organize segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its reportable segments based on revenue and operating income or loss. The accounting policies of the segments are the same as those described herein as well as those described in Note 2 to the audited consolidated financial statements in the 2016 Form 10-K. Corporate and unallocated amounts that do not relate to a reportable segment have been allocated to "Corporate". No asset information has been provided for the Company's reportable segments as management does not measure or allocate such assets on a reportable segment basis.
 
 
 
 
 
 
 
 
 
 
Information for the Company's reportable segments for the three months ended March 31, 2017 and 2016 are as follows:
Three Months Ended
March 31, 2017
Consumer Operations
Drug Development
Corporate
Consolidated
Total revenue
$
242,547

—

—

$
242,547

Interest income, net
$
—

—

77,854

$
77,854

Loss from operations
$
1,987,810

3,828,281

2,530,158

$
8,346,249

Three Months Ended
March 31, 2016
Consumer Operations
Drug Development
Corporate
Consolidated
Total revenue
$
—

—

—

$
—

Interest income, net
$
—

—

103,333

$
103,333

Loss from operations
$
2,929,355

4,059,043

2,707,396

$
9,695,794